Elsevier and PerkinElmer Informatics Announce Interoperability Between E-Notebook and Reaxys®
Frankfurt, Germany and Cambridge, MA, November 11, 2011 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, and PerkinElmer Inc. (PKI), a global leader focused on improving the health and safety of people and the environment, announced today that the chemistry workflow solution Reaxys® is now interoperable with PerkinElmer Informatics industry-leading E-Notebook. The cooperation between Elsevier and PerkinElmer ensures that Reaxys' best-in-class chemistry content from leading journals and patents is integrated with in-house, documented proprietary research findings captured via the PKI electronic laboratory notebook (ELN). The integration is available at no extra charge to customers who have both Reaxys and E-Notebook.
PKI Informatics E-Notebook is a broadly deployed ELN and is used by scientists in multiple disciplines from early discovery through development and into manufacturing. E-Notebook users looking for external, relevant chemistry data can pose queries in E-Notebook and immediately inspect results in Reaxys,a workflow solution for research chemists that provides access to an unparalleled depth of information on chemical compounds, related physical and pharmacological properties, and synthesis information. Researchers can get the experimentally validated information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Information from Reaxys can then be imported directly into appropriate sections in E-Notebook. This seamless transition from proprietary to published information and back again serves the needs of research scientist to integrate the relevant chemistry information into the research process directly at a point when they need it most.
“We are always looking for ways to streamline and add value to our customer’s workflows,” said Michael Stapleton, General Manager of PerkinElmer Informatics. “Our cooperation with Elsevier provides an often requested linkage between proprietary data in E-Notebook and published information in Reaxys.”
Mark van Mierle, Managing Director of Elsevier’s Pharma and Biotech Group, added, “Reaxys' information is relevant to a broad audience of researchers. In collaboration with PerkinElmer Informatics we extended Reaxys to support new workflows, benefiting the individual researcher and the organization.”
Reaxys® and the Reaxys® trademark are owned and protected by Elsevier Properties SA. All rights reserved.
# # #
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
Senior Manager Corporate Relations, Elsevier
+31 20 485 27 36